Improving Adherence — Money Isn't the Only Thing
2011; Massachusetts Medical Society; Volume: 365; Issue: 22 Linguagem: Inglês
10.1056/nejme1111558
ISSN1533-4406
AutoresLee Goldman, Arnold M. Epstein,
Tópico(s)Pharmaceutical Practices and Patient Outcomes
ResumoInterventions that both improve outcomes and save costs are unusual, but the provision of lifesaving medications to survivors of myocardial infarction is one such example.1 In the past, physicians' poor compliance with evidence-based guidelines was a major reason for suboptimal use of such medications. Now, with help from the dissemination of quality metrics, cost-saving medications such as beta-blockers, aspirin, and angiotensin-converting–enzyme (ACE) inhibitors are nearly universally prescribed to eligible patients after myocardial infarction,2,3 so the focus has switched from physician prescribing to patient adherence. The concept of value-based insurance design,4 which is encouraged by the Patient Protection and Affordable . . .
Referência(s)